RGDO News
Archived Headlines
- One US IPO planned for the week of Jul 8 07/08/13
- 6 US IPOs planned for the week of Jun 17 06/17/13
- Cardiovascular biotech Regado Biosciences sets terms for $75 million IPO 05/24/13
- US IPO Recap: Activity remains robust with five pricings, five setting terms and four new filers 05/06/13
- Regado Biosciences files for a $75 million IPO 04/29/13
Blood clot biotech rEVO Biologics sets terms for $50 million IPO
rEVO Biologics, which sells recombinant protein therapies to treat a rare blood clotting disorder, announced terms for its IPO on Thursday. The Framingham, MA-based company plans to raise $50 million by offering 3.6 million shares at a price range of $13 to $15....read more
US IPO Recap: Regado slashes valuation, three deals added to IPO pipeline
US IPO activity was light last week, as the market entered its typical end of August slow down. Regado Biosciences (RGDO), a cardiovascular disease biotech that has been trying to list since mid June, was finally able to complete its deal, but only after...read more
Regado Biosciences prices IPO at $4, below revised $5 price
Regado Biosciences, which is developing break-through anticoagulant system for cardiovascular surgeries, raised $43 million by offering 10.8 million shares, 2.4 million more than anticipated, at $4, below its lowered $5 price. The company had initially filed to...read more
Regado Biosciences decreases price to $5 and increases shares offered
Regado Biosciences, which is developing break-through anticoagulant system for cardiovascular surgeries, lowered the proposed deal size for its upcoming IPO on Monday. The Basking Ridge, NJ-based company now plans to raise $42 million by offering 8.4 million...read more